Artificial Intelligence for Early Drug Discovery – Part 1 Icon

Cambridge Healthtech Institute’s 5th Annual

Artificial Intelligence for Early Drug Discovery - Part 1

Early Decision-Making for Driving Drug Design and Lead Optimization

APRIL 11 - 12, 2023


The Artificial Intelligence for Early Drug Discovery conference brings together a diverse group of experts from chemistry, target discovery, pharmacology, and bioinformatics, to talk about the increasing use of computational tools, artificial intelligence (AI) models, machine learning (ML) algorithms, and data mining in preclinical drug development. The talks will highlight the opportunities and limitations of AI/ML-driven decision-making, using relevant case studies and research findings. The first part of the conference will focus on how AI/ML can help in drug design, hit identification, lead optimization, PK/PD predictions, and early safety assessments. The second part will focus on emerging computational tools and models to identify new drug targets, prioritize compounds for development and to help drive niche applications, such as predictions for targeted protein degradation.

6:00 pm MONDAY, APRIL 10: Dinner Short Course*
SC4: Generative and Predictive AI Modeling for Protein Inhibitors and Degraders

*Premium Pricing or separate registration required. See Short Courses page for details.

Please click here to continue to the agenda for Artificial Intelligence for Early Drug Discovery - Part 2

For more details on the conference, please contact:

Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute



For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431